SKYE Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Skye Bioscience's net margin of -49.65%. Skye Bioscience's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Skye Bioscience has a consensus price target of --, signalling upside risk potential of 576.69%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 557.2%. Given that Skye Bioscience has higher upside potential than NovaBay Pharmaceuticals, analysts believe Skye Bioscience is more attractive than NovaBay Pharmaceuticals.

Skye Bioscience has a beta of 1.719, which suggesting that the stock is 71.874% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Skye Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Skye Bioscience quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Skye Bioscience's net income of -$3.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Skye Bioscience's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience is 270.03x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oramed Pharmaceuticals has a net margin of -- compared to Skye Bioscience's net margin of --. Skye Bioscience's return on equity of -- beat Oramed Pharmaceuticals's return on equity of --.

Skye Bioscience has a consensus price target of --, signalling upside risk potential of 576.69%. On the other hand Oramed Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 37.71%. Given that Skye Bioscience has higher upside potential than Oramed Pharmaceuticals, analysts believe Skye Bioscience is more attractive than Oramed Pharmaceuticals.

Skye Bioscience has a beta of 1.719, which suggesting that the stock is 71.874% more volatile than S&P 500. In comparison Oramed Pharmaceuticals has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.699%.

Skye Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oramed Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience pays -- of its earnings as a dividend. Oramed Pharmaceuticals pays out -- of its earnings as a dividend.

Skye Bioscience quarterly revenues are --, which are smaller than Oramed Pharmaceuticals quarterly revenues of --. Skye Bioscience's net income of -$3.9M is higher than Oramed Pharmaceuticals's net income of -$19.6M. Notably, Skye Bioscience's price-to-earnings ratio is -- while Oramed Pharmaceuticals's PE ratio is 21.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience is 270.03x versus 36.14x for Oramed Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Skye Bioscience's net margin of -2357.27%. Skye Bioscience's return on equity of -- beat Palatin Technologies's return on equity of --.

Skye Bioscience has a consensus price target of --, signalling upside risk potential of 576.69%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1431.53%. Given that Palatin Technologies has higher upside potential than Skye Bioscience, analysts believe Palatin Technologies is more attractive than Skye Bioscience.

Skye Bioscience has a beta of 1.719, which suggesting that the stock is 71.874% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Skye Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Skye Bioscience quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Skye Bioscience's net income of -$3.9M is higher than Palatin Technologies's net income of -$7.8M. Notably, Skye Bioscience's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience is 270.03x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Skye Bioscience's net margin of --. Skye Bioscience's return on equity of -- beat Viking Therapeutics's return on equity of --.

Skye Bioscience has a consensus price target of --, signalling upside risk potential of 576.69%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 157.73%. Given that Skye Bioscience has higher upside potential than Viking Therapeutics, analysts believe Skye Bioscience is more attractive than Viking Therapeutics.

Skye Bioscience has a beta of 1.719, which suggesting that the stock is 71.874% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.884, suggesting its less volatile than the S&P 500 by 11.566%.

Skye Bioscience has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Skye Bioscience pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Skye Bioscience quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Skye Bioscience's net income of -$3.9M is higher than Viking Therapeutics's net income of -$24.9M. Notably, Skye Bioscience's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Skye Bioscience is 270.03x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.